Compare with LACTOSE INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs LACTOSE INDIA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN PHARMACEUTICALS LACTOSE INDIA SUVEN PHARMACEUTICALS/
LACTOSE INDIA
 
P/E (TTM) x 44.2 -27.9 - View Chart
P/BV x 11.6 1.4 818.2% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 SUVEN PHARMACEUTICALS   LACTOSE INDIA
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-21
LACTOSE INDIA
Mar-20
SUVEN PHARMACEUTICALS/
LACTOSE INDIA
5-Yr Chart
Click to enlarge
High Rs52536 1,479.6%   
Low Rs10314 717.1%   
Sales per share (Unadj.) Rs39.739.3 100.9%  
Earnings per share (Unadj.) Rs12.10.1 17,156.9%  
Cash flow per share (Unadj.) Rs13.43.9 342.4%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs46.433.6 137.9%  
Shares outstanding (eoy) m254.5710.19 2,498.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x7.90.6 1,248.7%   
Avg P/E ratio x25.9352.7 7.3%  
P/CF ratio (eoy) x23.56.4 368.1%  
Price / Book Value ratio x6.80.7 914.1%  
Dividend payout %16.50-   
Avg Mkt Cap Rs m79,953254 31,482.3%   
No. of employees `000NANA-   
Total wages/salary Rs m762119 641.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,097400 2,521.2%  
Other income Rs m1423 4,826.1%   
Total revenues Rs m10,240403 2,538.1%   
Gross profit Rs m4,43093 4,780.4%  
Depreciation Rs m31639 809.9%   
Interest Rs m11756 209.9%   
Profit before tax Rs m4,1391 418,119.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0530 390,118.5%   
Profit after tax Rs m3,0861 428,619.4%  
Gross profit margin %43.923.1 189.6%  
Effective tax rate %25.427.6 92.3%   
Net profit margin %30.60.2 16,977.0%  
BALANCE SHEET DATA
Current assets Rs m6,665197 3,378.2%   
Current liabilities Rs m3,215114 2,818.7%   
Net working cap to sales %34.220.8 164.4%  
Current ratio x2.11.7 119.8%  
Inventory Days Days20013 1,485.3%  
Debtors Days Days37064 581.7%  
Net fixed assets Rs m9,097635 1,431.8%   
Share capital Rs m255102 249.8%   
"Free" reserves Rs m11,554241 4,794.6%   
Net worth Rs m11,808343 3,444.0%   
Long term debt Rs m356337 105.7%   
Total assets Rs m15,762833 1,893.0%  
Interest coverage x36.51.0 3,584.7%   
Debt to equity ratio x01.0 3.1%  
Sales to assets ratio x0.60.5 133.2%   
Return on assets %20.36.8 300.6%  
Return on equity %26.10.2 12,428.1%  
Return on capital %35.08.3 420.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,90212 80,441.1%   
Fx outflow Rs m1,3692 61,111.6%   
Net fx Rs m8,53310 84,740.8%   
CASH FLOW
From Operations Rs m3,83476 5,061.2%  
From Investments Rs m-3,114-29 10,816.2%  
From Financial Activity Rs m-766-37 2,049.1%  
Net Cashflow Rs m-4510 -469.6%  

Share Holding

Indian Promoters % 60.0 49.1 122.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 13.8 0.7 2,035.3%  
FIIs % 8.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 50.9 78.6%  
Shareholders   96,532 15,988 603.8%  
Pledged promoter(s) holding % 0.0 47.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN PHARMACEUTICALS With:   IND. SWIFT  GUJ.THEMIS.  BDH INDUS.  LAURUS LABS   GODAVARI DRU  



Today's Market

Sensex Ends Above 61,000-Mark, Nifty Tops 18,300; Adani Ports, Wipro & Grasim Rally 5%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

This Proxy EV Stock Just got a Power Crisis Boost(Profit Hunter)

Oct 8, 2021

After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.

Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs...(Views On News)

Oct 8, 2021

These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.

Top 5 'Digital India' Stocks(Views On News)

Oct 6, 2021

These companies are leading the Government's US$1 tn 'Digital India' initiative.

5 Exciting 'Unlisted' Companies and How to Play Them(Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN PHARMACEUTICALS SHARE PRICE


Oct 14, 2021 (Close)

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS - UNICK FIX-A-FORM AND PRINTERS COMPARISON

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS